【Abstract】 Objective: To determine the effects of neoadjuvant chemotherapy in patient with stageⅠb2-Ⅱb adenocarcinoma of the uterine cervix. Methods: 23 patients with StageⅠb2-Ⅱb Adenocarcinoma of The Uterine Cervix were chosen for the observed group. They received 1 to 2 courses of treatment consisting of cisplatin and paclitaxel（TP regimen）. After the chemotherapy regimen was completed, the patients underwent radical surgery. A group of 19 cases with the same diagnoses received radical surgery alone. This group was considered the control group. The patients were followed. The pathology result, the rate of recurrence and the survival time were compared between the two groups. Results: The effective rate of chemotherapy for patients in the observed group was (CR+PR) 69.57%. In the observed group, the postoperative rate of cervical deep myometrial invasion, parametrial infiltration rate, pelvic lymph node metastasis rate and vaginal margin rate were significantly lower compared to the control group (P<0.05). There wasn’t difference in operative time of the two groups, but blood loose of the observed group were significantly less than the controls (P<0.05). The 1-year/3-years survival rate of the observed group were significantly longer than the controls, and the relapse rate were significantly lower for patients in the observed group. Conclusion: Neoadjuvant chemotherapy is beneficial for diminishing gross tumor volume, reducing the rate of lymph node metastasis and relapse, and prolonging the survival time of patients with stageⅠb2-Ⅱb adenocarcinoma of the uterine cervix. The TP regimen is effective in the treatment of patient with stageⅠb2-Ⅱb adenocarcinoma of the uterine cervix.